



The relative strengths and weaknesses of GT Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GT Biopharma Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 1,535% points. The greatest weakness of GT Biopharma Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 70% points.

The company's Economic Capital Ratio, given in the ranking table, is 225%, being 180% points above the market average of 46%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 576 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 2,679 |
| Liabilities, Non-Current | 0 |
| Other Assets | 253,786 |
| Other Compr. Net Income | 0 |
| Other Expenses | 0 |
| Other Liabilities | 0 |
| Other Net Income | -7,677 |
| Other Revenues | 0 |
| Property and Equipment | 6.0 |
| Research and Development | 1,068 |
| Selling, General and Administrative Expense | 134,502 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 254,368 |
| Liabilities | 2,679 |
| Expenses | 135,570 |
| Revenues | 0 |
| Stockholders Equity | 251,689 |
| Net Income | -143,247 |
| Comprehensive Net Income | -143,247 |
| Economic Capital Ratio | 225% |